Filing Flows › Spero Therapeutics (SPRO) › Q2 2025
Spero Therapeutics (SPRO) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Spero Therapeutics (SPRO) reported revenue of $14.2M for the second quarter 2025 (Q2 2025), +39% from a year earlier and +142% from the quarter before. Operating margin was -17.2%, net loss $1.7M (12.0% of revenue).
Spero Therapeutics, Q2 2025: revenue $14.2M (+39% year over year), operating margin -17.2%, net loss $1.7M, operating cash flow −$17.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.2M | +142% | +39% |
| Operating profit | −$2.4M | — | — |
| Net earnings | −$1.7M | — | — |
| Operating cash flow | −$17.7M | — | — |
What changed
Revenue was $14.2M in Q2 2025, up 39% year over year and up 142% from the previous quarter. Collaboration Revenue Related Party was the largest line at 83% of revenue. Collaboration Revenue Related Party added $5.9M year over year (up 100%), 148% of the total change. Grant Revenue declined 43%.
Operating costs exceeded revenue by $2.4M, an operating margin of -17.2%. Total costs fell 43% while revenue rose 39%. The quarter ended with a net loss of $1.7M, narrower than the previous quarter's $13.9M loss. Non-operating items added $744K, -44% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$17.7M. Non-cash charges added back $714K of share-based compensation. Working capital and other items used $16.7M.
Questions
What was Spero Therapeutics' revenue in the second quarter 2025?
Spero Therapeutics (SPRO) reported revenue of $14.2M for the second quarter 2025 (Q2 2025), +39% from a year earlier and +142% from the quarter before.
Was Spero Therapeutics profitable in the second quarter 2025?
Operating loss was $2.4M (-17.2% of revenue) and net loss $1.7M.
Source: Spero Therapeutics 10-Q on SEC EDGAR.